| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
L-Praziquanamine targets calcium channels in parasites. By disrupting calcium channel function, it causes worm muscle contraction and death, which is the basis for its antiparasitic activity. It is also used as an intermediate in the synthesis of chiral stationary phases for HPLC enantioseparations.
|
|---|---|
| ln Vitro |
The enantiomer of paziquanamine is called L-Praziquanamine [1].
In vitro, L-Praziquanamine is used in antiparasitic research to study calcium channel function in parasites. Its activity is assessed by measuring its effects on worm motility, muscle contraction, and calcium flux in parasitic models. |
| ln Vivo |
In vivo activity data for L-Praziquanamine are limited in the available literature. As an enantiomer of praziquanamine, it is used in research to study the stereospecific effects of praziquantel analogs. Further in vivo studies are needed to characterize its antiparasitic efficacy.
|
| Enzyme Assay |
In vitro receptor/channel binding assays for L-Praziquanamine are not typically performed, as its primary use is as an intermediate or research tool. However, its effects on calcium channels can be assessed using electrophysiological techniques or calcium flux assays in parasite preparations or cells expressing parasite calcium channels.
|
| Cell Assay |
In vitro cellular assays for L-Praziquanamine are performed using parasite models, such as schistosomes or other helminths. Parasites are treated with the compound, and their motility, muscle contraction, and viability are assessed. The compound's ability to disrupt calcium homeostasis and induce paralysis is quantified.
|
| Animal Protocol |
In vivo animal experiments for L-Praziquanamine are not extensively documented. As a research compound, in vivo studies would typically involve administration to animal models of parasitic infection. The compound would be administered via oral or parenteral routes, and efficacy would be assessed by measuring parasite burden and worm motility.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of L-Praziquanamine have not been systematically characterized. The compound has a molecular weight of 202.25, molecular formula C12H14N2O. It should be stored as a powder at -20°C for up to 3 years or at 4°C for up to 2 years. Further PK studies are needed to determine its absorption, distribution, metabolism, and excretion profile.
|
| Toxicity/Toxicokinetics |
Toxicological data for L-Praziquanamine are not extensively reported. As a research-use compound, its safety profile has not been formally evaluated in comprehensive preclinical toxicology studies. The compound is intended for research purposes only and is not approved for human therapeutic use. Standard laboratory safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
L-Praziquanamine is also known as (+)-Praziquanamine. It is the L-enantiomer of praziquanamine and is a natural product. It is used as an intermediate in the synthesis of labeled praziquantel derivatives and in antiparasitic research. This product is for research use only.
|
| Molecular Formula |
C12H14N2O
|
|---|---|
| Molecular Weight |
202.2524
|
| Exact Mass |
202.111
|
| CAS # |
99746-73-3
|
| Related CAS # |
D-Praziquanamine;55375-92-3
|
| PubChem CID |
24797049
|
| Appearance |
White to off-white solid powder
|
| LogP |
0.982
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
15
|
| Complexity |
266
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C1CN2[C@H](CNCC2=O)C3=CC=CC=C31
|
| InChi Key |
GTRDOUXISKJZGL-LLVKDONJSA-N
|
| InChi Code |
InChI=1S/C12H14N2O/c15-12-8-13-7-11-10-4-2-1-3-9(10)5-6-14(11)12/h1-4,11,13H,5-8H2/t11-/m1/s1
|
| Chemical Name |
(11bS)-1,2,3,6,7,11b-hexahydropyrazino[2,1-a]isoquinolin-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~494.44 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (12.36 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (12.36 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (12.36 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.9444 mL | 24.7219 mL | 49.4438 mL | |
| 5 mM | 0.9889 mL | 4.9444 mL | 9.8888 mL | |
| 10 mM | 0.4944 mL | 2.4722 mL | 4.9444 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
